ClinicalTrials.gg
SuspendedNCT05441488MAXIMSUpdated May 6, 2026

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

A Phase 3 interventional study of Placebo and Masitinib (4.5) in Progressive Multiple Sclerosis, sponsored by AB Science. Suspended at 37 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Why this study was suspended
The study has been suspended but may start again in the future.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France — 4 open to participants now, 10 under way, 8 of them phase 3. Multiple Sclerosis, Chronic Progressive · France.

Planned enrollment
11th of 28
800 · median 696
Started
2022
the only one that year
Phase 3
18 of 32
3 open now
Registered
26th of 32
by date
Lead sponsor
2 of 32
AB Science

Among the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, this one is the 11th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is one of 18 in phase 3, and was the 26th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

4 of the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast cells and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). This is a multicenter, double-blind, randomized, placebo-controlled, comparative study of oral masitinib in the treatment of patients with progressive MS who were progressing but not clinically active.

03

Conditions studied

  • Progressive Multiple Sclerosis

Keywords

  • Primary progressive MS
  • Non-active secondary progressive MS
  • Tyrosine kinase inhibitor
  • PPMS
  • SPMS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • Patients with either primary progressive or secondary progressive multiple sclerosis with onset of symptoms at least five years before baseline and with no relapse diagnosed according to the 2017 revised McDonald's criteria at least two years before screening
  • Patients with Expanded Disability Status Scale (EDSS) score between 3.0 to 6.0 (both inclusive) at screening and baseline
  • Patients with an EDSS score progression ≥1 point with no improvement during 2 years
  • Absence of T1 Gadolinium-enhancing brain lesions as measured by MRI at screening

Main exclusion criteria include:

  • Patients suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions observed at screening
  • Inability to complete screening MRI ( for MRI) and/or any known allergy or or any contra-indication to gadolinium macrocyclic
  • Patients treated with other disease modifying treatments in the time frames and conditions mentioned under previous treatment wash out period, assessed at baseline
  • Patients with lymphocytes \<1.0 × 10\^9/L at screening and at baseline
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Masitinib (4.5)

    Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.

    Drug: Masitinib (4.5)

  • Placebo comparator
    Placebo

    Participants receive a matched dose placebo, given orally twice daily.

    Drug: Placebo

Interventions

  • DrugPlacebo

    treatment per os

    Also known as: Placebo Oral Tablet

  • Masitinib (titration to 4.5 mg/kg/day)

    Also known as: AB1010

06

What researchers measure

Primary outcomes

  1. Time to confirmed progression

    Time to disability progression, confirmed by two consecutive visits, wherein progression of disability is measured by the Expanded Disability Status Scale (EDSS) with progression defined as a 1-point worsening for baseline EDSS score ≤5.5, or 0.5-point worsening for baseline EDSS score \>5.5. The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The EDSS provides a total score on a scale that ranges from 0 to 10, in 0.5-point increments, with higher scores indicating greater disability. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.

    Time frame: 96 weeks

Secondary outcomes

  1. Time to Expanded Disability Status Scale (EDSS) score of 7.0

    Time to reach EDSS score of 7 from baseline up to week 96, wherein EDSS score of ≥7.0 represents wheelchair dependency. The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The EDSS provides a total score on a scale that ranges from 0 to 10, in 0.5-point increments, with higher scores indicating greater disability. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.

    Time frame: 96 weeks

  2. Overall Change in Expanded Disability Status Scale (EDSS) Score

    Change from baseline on the EDSS, calculated using repeated measures methodology on all time points measured over 96 weeks (i.e., a population-averaged score comprising consecutive data points from each patient). The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The EDSS provides a total score on a scale that ranges from 0 to 10, in 0.5-point increments, with higher scores indicating greater disability. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.

    Time frame: 96 weeks

  3. Brain Magnetic Resonance Imaging Assessments

    Change in baseline brain volume and lesions will be measured and assessed

    Time frame: 96 weeks

  4. Multiple Sclerosis Quality of Life (MSQOL)-54

    Change in quality of life assessment instrument MSQOL-54 The MS Quality of Life Instrument (MSQoL-54) is a structured self-report questionnaire that is used to assess the impact of MS on the individual's well-being. It consists of 52 items combined in 12 subscales, and two single items. Higher scores indicate a better quality of life.

    Time frame: 96 weeks

07

Study locations

37 sites
  • Service de Neurologie Hôpital Henri-Mondor
    Créteil, France
  • Hôpital Roger Salengro
    Lille, France
  • Hôpital Pasteur - CHU de Nice
    Nice, France
  • Centre Hospitalier Universitaire Nimes - Service de Neurologie
    Nîmes, France
  • Centre hospitalier intercommunal de Poissy-Saint-Germain-en-Laye
    Poissy, France
  • Le Centre hospitalier universitaire de Poitiers
    Poitiers, France
  • Centre Hospitalier Universitaire de Rouen
    Rouen, France
  • Centre Hospitalier Universitaire de Strasbourg
    Strasbourg, France
  • Centre Hospitalier Universitaire Toulouse
    Toulouse, France
  • Athens Naval Hospital
    Athens, Greece
  • Eginition Hospital, Athens University Medical School
    Athens, Greece
  • General University Hospital of Larissa
    Larissa, Greece
  • AHEPA University Hospital, Aristotle University of Thessaloniki
    Thessaloniki, Greece
  • Private Clinic ELPIS
    Volos, Greece
  • Azienda Ospedaliero Universitaria Policlinico "G.Rodolico -San Marco"
    Catania, Italy
  • Nzoz Neuro-Medic
    Katowice, Poland
  • NOVI-MED
    Ksawerów, Poland
  • Centrum Neurologii Krzysztof Selmaj
    Lodz, Poland
  • NZOZ Neuro-Med
    Lublin, Poland
  • Generała Jarosława Dąbrowskiego
    Oświęcim, Poland
  • NZOZ Neuro-Kard
    Poznan, Poland
  • Clinical Best Solutions
    Warsaw, Poland
  • State Budgetary Institution of Health of the City of Moscow City Polyclinic #2
    Moscow, Russia
  • Perm Regional Clinical Hospital
    Perm, Russia
  • City Hospital No. 40 Kurortny District
    Saint Petersburg, Russia
  • LLC "Center of socially significant diseases"
    Saint Petersburg, Russia
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Universitario de Cruces
    Bilbao, Spain
  • Gregorio Marañón General University Hospital
    Madrid, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • Sahlgrenska University Hospital
    Gothenburg, Sweden
  • Centrum för neurologi
    Stockholm, Sweden
  • Lviv Regional Clinical Hospital
    Lviv, Ukraine
  • Rivne Regional Specialized Dispensary for Radiation Protection of the Population Municipal Enterprise
    Rivne, Ukraine
  • Communal Non-Profit Enterprise "Ternopil Regional Clinical Psychoneurological Hospital" of Ternopil Regional Council, Department of Neurology #1
    Ternopil, Ukraine
  • Salutem Medical Center
    Vinnytsia, Ukraine
08

References and documents

Publications

  • Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. PubMed 35190477 ↗
  • Vermersch P, Benrabah R, Schmidt N, Zephir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36. PubMed 22691628 ↗
  • Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1. PubMed 36048877 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2028, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 1, 2022
StartActual
Jun 28, 2022
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05441488
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Jun 28, 2022
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 6, 2026

Study contacts

Patrick VERMERSCH, MD, PhD
principal investigator · University of Lille, CHU of Lille, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion